Grant: Engage Grants Program
University of Alberta
$25,000.00
Sorbent surfaces for specific removal of carbamylated albumin from blood
EF 2016-17
Résumé
Kidneys clean the blood through removing molecules that would otherwise cause our body harm. Damaged kidneys no longer remove molecules that lead to severe, and often fatal, conditions where the patient is poisoned just by living a normal life. To combat this, engineers and scientists have developed membranes to help remove these molecules from the blood, which is called Dialysis. Dialysis is relatively good at removing small molecules from the blood because they can easily pass through. Although ~23,000 Canadians are treated for ~CDN$1.4 billion, annually, patients are still dieing at a similar rate as 20 yrs ago. Moreover, the technology used for dialysis has also not changed during this time. The problem occurs when the molecules are too big to pass through the dialysis membrane, they are then kept in the blood. Similar to trying to get a fly out of the house, they are kept inside because they cannot pass through the window screen. Chief Medical, the only GMP accreditated manufacturing facility in Western Canada for dialysis equipment and consumables wants to develop new devices for tackling this issue, but they can only do this through collaborating with Unsworth Labs. Just like our fly, we want to develop a sticky 'tape' that these harmful molecules in the blood can stick to and be removed. 50 molecules accumulate in dialysis patients that are considered too large to move through existing membranes. We will use this funding to design sticky-molecules to grab these toxic molecules in the blood and bind them so that the blood gets cleaner. The cool thing is, we think we can design sticky-molecules that precisely target these toxins, without binding other things that are good for us. It is expected we can then develop similar sticky-molecules for the remaining toxins in the blood and increase patient lifespan. Finally, this proof-of-concept work could easily be transitioned into commercial practice and lead to an exciting transition in the state-of-the-art in treatment for patients who need dialysis to live.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
492562-2015
Name nom
Unsworth, Larry
Department département
Chemical and Materials Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
1
Nb partie
1
Application title
Sorbent surfaces for specific removal of carbamylated albumin from blood
Keyword
NSERC
Application summary
Kidneys clean the blood through removing molecules that would otherwise cause our body harm. Damaged kidneys no longer remove molecules that lead to severe, and often fatal, conditions where the patient is poisoned just by living a normal life. To combat this, engineers and scientists have developed membranes to help remove these molecules from the blood, which is called Dialysis. Dialysis is relatively good at removing small molecules from the blood because they can easily pass through. Although ~23,000 Canadians are treated for ~CDN$1.4 billion, annually, patients are still dieing at a similar rate as 20 yrs ago. Moreover, the technology used for dialysis has also not changed during this time. The problem occurs when the molecules are too big to pass through the dialysis membrane, they are then kept in the blood. Similar to trying to get a fly out of the house, they are kept inside because they cannot pass through the window screen. Chief Medical, the only GMP accreditated manufacturing facility in Western Canada for dialysis equipment and consumables wants to develop new devices for tackling this issue, but they can only do this through collaborating with Unsworth Labs. Just like our fly, we want to develop a sticky 'tape' that these harmful molecules in the blood can stick to and be removed. 50 molecules accumulate in dialysis patients that are considered too large to move through existing membranes. We will use this funding to design sticky-molecules to grab these toxic molecules in the blood and bind them so that the blood gets cleaner. The cool thing is, we think we can design sticky-molecules that precisely target these toxins, without binding other things that are good for us. It is expected we can then develop similar sticky-molecules for the remaining toxins in the blood and increase patient lifespan. Finally, this proof-of-concept work could easily be transitioned into commercial practice and lead to an exciting transition in the state-of-the-art in treatment for patients who need dialysis to live.